DU-127090 Solvay/H Lundbeck.
DU-127090 is a mixed dopamine antagonist/serotonin agonist in development by Solvay and H Lundbeck as a potential treatment for psychosis and schizophrenia, for which it is in phase II clinical trials. In August 2002, phase II trials were ongoing and Lundbeck expected to commence phase III trials in 2003 and file an NDA after 2004. DU-127090 is also under development for Parkinson's disease, for which it is in phase I clinical trials.
Wolf
William
W
Hines VA Hospital, Loyola University Chicago School of Medicine, Hines, IL 60141, USA. William.Wolf@med.va.gov
D014150:Antipsychotic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001583:Benzoxazoles; D001713:Biphenyl Compounds / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D018491:Dopamine Agonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists; D011985:Receptors, Serotonin / Q000187:drug effects; D044263:Receptors, Serotonin, 5-HT1; D012559:Schizophrenia / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D001583:Benzoxazoles; D001713:Biphenyl Compounds; D018491:Dopamine Agonists; D010879:Piperazines; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D017366:Serotonin Receptor Agonists; C509981:bifeprunox